3Klamann E, Lingens F. Degradation of (-)-ephedrine by Pseudomonas putida. Detection of ( - )-ephedrine: NAD+-oxidoreductase from Arthrobacter globiformis[J]. Z Naturforsch C,1980,35(1-2) :80-87.
4Singh A,Althoff R, Martineau R J, Jacobson J. Pramipexole, ropinirole,and mania in Parkinson's disease[J]. Am J Psychiatry,2005,162:814-815.
5Moller J C,Oertel W H, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Par kinson's disease results from a European multieenter trial[J].Mov Disord, 2005,20 : 602-610.
6Joyce J N,Woolsey C, Ryoo H, Borwege S, Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease,and downregulates the dopamine transporter via the D3 receptor[J]. BMC Biol, 2004,2 : 22.
7Biglan K M,Holloway R G. A review of pramipexole and its clinical utility in Parkinson's disease[J]. Expert Opin Pharma cother, 2002,3 :197-210.
8Hubble J P. Pre-clinical studies of pramipexole: clinical rele vance[J].Eur J Neurol,2000,7 Suppl 1:15-20.
9Hubble J P,Koller W C, Cutler N R, Sramek J J, Friedman J, Goetz C,et al. Pramipexole in patients with early Parkinson' s disease[J]. Clin Neuropharmacol, 1995,18 : 338-347.
10Abramova N A, Cassarino D S, Khan S M, Painter T W, Bennett J P Jr. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma[J]. J Neurosci Res, 2002,67:494-500.
